Assembly Biosciences' (ASMB) Sell (D-) Rating Reiterated at Weiss Ratings

Key Points

• Assembly Biosciences received a "sell (D-)" rating from Weiss Ratings, reflecting ongoing concerns from analysts regarding the company's stock performance.
• Despite a negative rating from Weiss, several other firms have initiated coverage with positive outlooks, including a "buy" rating and price target of $50.00 from HC Wainwright.
• The company's stock has experienced significant volatility, with a one-year low of $7.75 and a high of $27.17, while it currently trades around $25.50.

Assembly Biosciences (NASDAQ:ASMB - Get Free Report)'s stock had its "sell (d-)" rating reaffirmed by equities research analysts at Weiss Ratings in a note issued to investors on Wednesday,Weiss Ratings reports.

ASMB has been the subject of a number of other research reports. Citizens Jmp initiated coverage on Assembly Biosciences in a research report on Wednesday, September 24th. They set an "outperform" rating and a $38.00 price objective for the company. HC Wainwright initiated coverage on Assembly Biosciences in a research report on Monday, August 18th. They set a "buy" rating and a $50.00 price objective for the company. JMP Securities started coverage on Assembly Biosciences in a research report on Wednesday, September 24th. They set a "market outperform" rating and a $38.00 price objective for the company. Zacks Research upgraded Assembly Biosciences to a "hold" rating in a research report on Tuesday, August 19th. Finally, Citigroup started coverage on Assembly Biosciences in a research report on Wednesday, September 24th. They set an "outperform" rating for the company. Five analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $41.25.

Assembly Biosciences Stock Performance

Shares of NASDAQ ASMB traded up $1.64 during trading on Wednesday, reaching $25.50. The stock had a trading volume of 151,694 shares, compared to its average volume of 59,005. Assembly Biosciences has a one year low of $7.75 and a one year high of $27.17. The stock has a market cap of $195.59 million, a PE ratio of -4.57 and a beta of 0.60. The firm's 50 day moving average price is $23.56 and its two-hundred day moving average price is $17.41.

Assembly Biosciences (NASDAQ:ASMB - Get Free Report) last issued its quarterly earnings results on Wednesday, August 6th. The biopharmaceutical company reported ($1.33) earnings per share for the quarter, beating analysts' consensus estimates of ($1.73) by $0.40. Assembly Biosciences had a negative return on equity of 149.01% and a negative net margin of 117.20%.The business had revenue of $9.63 million during the quarter, compared to the consensus estimate of $5.30 million. On average, research analysts expect that Assembly Biosciences will post -6.87 earnings per share for the current year.

Hedge Funds Weigh In On Assembly Biosciences

Institutional investors have recently bought and sold shares of the stock. American Century Companies Inc. purchased a new stake in shares of Assembly Biosciences in the 1st quarter valued at approximately $113,000. Acadian Asset Management LLC raised its stake in Assembly Biosciences by 42.1% during the 1st quarter. Acadian Asset Management LLC now owns 23,027 shares of the biopharmaceutical company's stock valued at $219,000 after purchasing an additional 6,823 shares during the period. Palumbo Wealth Management LLC boosted its position in shares of Assembly Biosciences by 57.4% in the first quarter. Palumbo Wealth Management LLC now owns 17,986 shares of the biopharmaceutical company's stock worth $172,000 after buying an additional 6,559 shares during the period. Finally, Geode Capital Management LLC boosted its position in shares of Assembly Biosciences by 6.9% in the second quarter. Geode Capital Management LLC now owns 51,015 shares of the biopharmaceutical company's stock worth $925,000 after buying an additional 3,312 shares during the period. Hedge funds and other institutional investors own 19.92% of the company's stock.

About Assembly Biosciences

Assembly Biosciences, Inc, a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.